相关实验视频

Updated: Jul 23, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

埃拉拉纳塔马巴:在多发性骨髓瘤治疗中是一种新的有前途的BispAb

Sebastian Grosicki¹, Martyna Bednarczyk¹, Karolina Kociszewska¹

¹Medical University of Silesia, Department of Hematology and Cancer Prevention, Katowice, Slaskie, Poland.

Expert review of anticancer therapy

|July 12, 2023

概括

针对BCMA和CD3的新型双特异性抗体Elranatamab对治疗复发性多发性骨髓瘤有希望. 与静脉注射途径相比,皮下注射可能会提供更好的安全性和有效性.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

多发性骨髓瘤是一种无法治愈的B细胞恶性瘤,其特征是血细胞增殖.
尽管治疗进展,多发性骨髓瘤经常复发,需要新的治疗策略.
对于提供持续反应和长期持续的治疗方法,存在着未满足的需求.

研究的目的:

审查用于多发性骨髓瘤治疗的新型双特异性抗体elranatamab.
讨论它的作用机制,施用途径和初步临床发现.

主要方法:

关于elranatamab的初步临床数据和摘要介绍的审查.
分析elranatamab作为针对BCMA和CD3.3的双特异抗体的结构.
皮下与静脉注射方式的比较.

主要成果:

埃拉拉纳塔马布对BCMA和CD3具有优化的结合亲和力,具有强大的T细胞介导的抗髓瘤活性.
与静脉注射相比,ELRANATAMAB的皮下使用与不良事件发生率较低有关.
对elranatamab的临床研究初步结果令人鼓舞.

结论:

埃尔拉纳塔马巴 (Elranatamab) 代表了对多发性骨髓瘤的一种有前途的新疗法.
需要进一步的临床研究来确定其疗效和安全性.
皮下注射可能是elranatamab治疗的首选途径.

关键词:

这就是为什么BCMABCMABCMA.这是BispAbs.埃尔拉纳塔马巴的意思是在 MM MM MM MM 里面.多发性骨髓瘤是多发性骨髓瘤的一种.

更多相关视频

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...